Davis To Shepherd Merck & Co. Toward The Post-Keytruda Era, As Frazier Exits

 
• By Jessica Merrill

Merck & Co.'s CFO Robert Davis will succeed Ken Frazier as CEO. Frazier was one of the architects of the Schering-Plough acquisition, which shaped the pharma for the next decade and delivered its top-selling drug, Keytruda.

Robert M. Davis and Kenneth Frazier
Merck's incoming CEO Robert Davis with Ken Frazier • Source: Merck & Co.

More from Leadership

More from Scrip